Skip to main content
Timothy Pardee, MD, Oncology, Winston Salem, NC

TimothyPardeeMDPhD

Oncology • Winston Salem, NC

Hematologic Oncology

Associate Professor, Internal Medicine, Wake Forest University School of Medicine

Join to view full profile

Dr. Pardee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Pardee's full profile

Already have an account?

  • Office

    1 S Hawthorne Rd
    # Hanes
    Winston Salem, NC 27157
    Phone+1 336-716-5847
    Fax+1 336-716-2067

Education & Training

  • Stony Brook Medicine/University Hospital
    Stony Brook Medicine/University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2009
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2003 - 2005
  • Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
    Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2003

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2025
  • NY State Medical License
    NY State Medical License 2005 - 2010
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements o...
    Timothy S. Pardee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Evaluating the Utilization of All-Trans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia
    Timothy S. Pardee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Multicentre, Open Label, Randomized Phase III Study of Cpi-613¬ (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cyt... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly ActiveClinically Relevant Abstract 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
    Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology AssociationJune 16th, 2018
  • WFIRM Scientists Study Space Radiation Health Effects to Keep Astronauts Safe
    WFIRM Scientists Study Space Radiation Health Effects to Keep Astronauts SafeNovember 14th, 2017
  • Pappas Capital and Wake Forest Innovations Announce First Investments by the Catalyst Fund
    Pappas Capital and Wake Forest Innovations Announce First Investments by the Catalyst FundJanuary 11th, 2017
  • Join now to see all

Professional Memberships

Dr. Timothy Pardee, Dr. Timothy Pardee, MD, Dr. T Pardee